Polyestradiol phosphate/medroxyprogesterone acetate
Polyestradiol phosphate/medroxyprogesterone acetate (PEP/MPA) is a combination of polyestradiol phosphate (PEP), an estrogen, and medroxyprogesterone acetate (MPA), a progestin, which was studied in the 1960s as a long-lasting combined injectable contraceptive for women but was never marketed. It was administered by intramuscular injection once every 3 months and contained 40 mg PEP and 150 mg MPA. The combination was studied in a sample of 99 premenopausal women and was found to be effective in preventing pregnancy, but caused menstrual irregularities similar to those of MPA alone as a progestogen-only injectable contraceptive. PEP was included in the formulation to prevent estrogen deficiency and reduce menstrual abnormalities caused by MPA during long-term contraceptive therapy.
Q1779868
combination
Concept
Q7226308
polyestradiol phosphate
Concept
Q48841284
estrogen
Concept
Q2823834
medroxyprogesterone acetate
MISC
Q50383885
progestin
Concept
Q3824054
combined injectable contraceptive
UNK
Q432083
intramuscular injection
Concept
Q11995
pregnancy
Concept
Q6073603
menstrual irregularities
UNK
Q28209219
progestogen-only injectable contraceptive
UNK
Q5959600
estrogen deficiency
Concept
Q85793873
Polyestradiol phosphate/medroxyprogesterone acetate
Concept
1960-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1960
DATE
+3^^http://www.w3.org/2001/XMLSchema#decimal
3
NUMBER
+40^^http://www.w3.org/2001/XMLSchema#decimal
40
NUMBER
+99^^http://www.w3.org/2001/XMLSchema#decimal
99
NUMBER
instance of